The combination of PARP inhibition and DNAJB1-PRKACA neoepitope-based peptide vaccine could have positively affected the vaccination response and the prolonged relapse-free survival of the FL-HCC patient based on the beneficial impact of DNA-damaging agents on tumor immunogenicity, which was previously reported for the combination of PARP inhibition and ICIs51,52. The gene discussed is DNAJB1; the disease is hepatocellular carcinoma.